Literature DB >> 11601991

Biosynthesis of sialylated lipooligosaccharides in Haemophilus ducreyi is dependent on exogenous sialic acid and not mannosamine. Incorporation studies using N-acylmannosamine analogues, N-glycolylneuraminic acid, and 13C-labeled N-acetylneuraminic acid.

B Schilling1, S Goon, N M Samuels, S P Gaucher, J A Leary, C R Bertozzi, B W Gibson.   

Abstract

Haemophilus ducreyi is a Gram-negative bacterium that causes chancroid, a sexually transmitted disease. Cell surface lipooligosaccharides (LOS) of H. ducreyi are thought to play important biological roles in host infection. The vast majority of H. ducreyi strains contain high levels of sialic acid (N-acetylneuraminic acid, NeuAc) in their LOS. Here we investigate the biosynthetic origin of H. ducreyi sialosides by metabolic incorporation studies using a panel of N-acylmannosamine and sialic acid analogues. Incorporation of sialosides into LOS was assessed by matrix-assisted laser desorption and electrospray ionization mass spectrometry. A Fourier transform ion cyclotron resonance mass spectrometer provided accurate mass measurements, and a quadrupole time-of-flight instrument was used to obtain characteristic fragment ions and partial carbohydrate sequences. Exogenously supplied N-acetylmannosamine analogues were not converted to LOS-associated sialosides at a detectable level. In contrast, exogenous (13)C-labeled N-acetylneuraminic acid ([(13)C]NeuAc) and N-glycolylneuraminic acid (NeuGc) were efficiently incorporated into LOS in a dose-dependent fashion. Moreover, approximately 1.3 microM total exogenous sialic acid was sufficient to obtain about 50% of the maximum production of sialic acid-containing glycoforms observed under in vitro growth conditions. Together, these data suggest that the expressed levels of sialylated LOS glycoforms observed in H. ducreyi are in large part controlled by the exogenous concentrations of sialic acid and at levels one might expect in vivo. Moreover, these studies show that to properly exploit the sialic acid biosynthetic pathway for metabolic oligosaccharide engineering in H. ducreyi and possibly other prokaryotes that share similar pathways, precursors based on sialic acid and not mannosamine must be used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601991     DOI: 10.1021/bi0107849

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  A biosynthetic strategy for re-engineering the Staphylococcus aureus cell wall with non-native small molecules.

Authors:  James W Nelson; Alexander G Chamessian; Patrick J McEnaney; Ryan P Murelli; Barbara I Kazmierczak; Barbara I Kazmiercak; David A Spiegel
Journal:  ACS Chem Biol       Date:  2010-10-05       Impact factor: 5.100

2.  Sialylation of lipooligosaccharides is dispensable for the virulence of Haemophilus ducreyi in humans.

Authors:  Stanley M Spinola; Wei Li; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Barry P Katz; Robert S Munson
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

3.  PmST2: a novel Pasteurella multocida glycolipid α2-3-sialyltransferase.

Authors:  Vireak Thon; Kam Lau; Hai Yu; Bao K Tran; Xi Chen
Journal:  Glycobiology       Date:  2011-04-21       Impact factor: 4.313

4.  Sialic acid catabolism confers a competitive advantage to pathogenic vibrio cholerae in the mouse intestine.

Authors:  Salvador Almagro-Moreno; E Fidelma Boyd
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 5.  Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications.

Authors:  Christopher T Saeui; Esteban Urias; Lingshu Liu; Mohit P Mathew; Kevin J Yarema
Journal:  Glycoconj J       Date:  2015-05-01       Impact factor: 2.916

6.  Identification of a novel sialic acid transporter in Haemophilus ducreyi.

Authors:  Deborah M B Post; Rachna Mungur; Bradford W Gibson; Robert S Munson
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Experimental Design Considerations for In Vitro Non-Natural Glycan Display via Metabolic Oligosaccharide Engineering.

Authors:  Elaine Tan; Ruben T Almaraz; Hargun S Khanna; Jian Du; Kevin J Yarema
Journal:  Curr Protoc Chem Biol       Date:  2010-09-01

8.  Sialic Acid metabolism and systemic pasteurellosis.

Authors:  Susan M Steenbergen; Carol A Lichtensteiger; Ruth Caughlan; Jackie Garfinkle; Troy E Fuller; Eric R Vimr
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

9.  Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid.

Authors:  Rachel E Taylor; Christopher J Gregg; Vered Padler-Karavani; Darius Ghaderi; Hai Yu; Shengshu Huang; Ricardo U Sorensen; Xi Chen; Jaime Inostroza; Victor Nizet; Ajit Varki
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

10.  Characterization of N-acetylneuraminic acid synthase isoenzyme 1 from Campylobacter jejuni.

Authors:  Appavu K Sundaram; Lee Pitts; Kamilah Muhammad; Jing Wu; Michael Betenbaugh; Ronald W Woodard; Willie F Vann
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.